Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13126454 | 0.85 | POLB (0.49) | LMNASMN1; SMN2ALDH1A1RAB9ACYP1A2 | |
| SCHEMBL3580133 | 0.85 | LMNA (0.54) | LMNASMN1; SMN2ALDH1A1RAB9ACYP1A2 | |
| SCHEMBL26418189 | 0.83 | LMNA (0.52) | LMNASMN1; SMN2ALDH1A1RAB9ACYP1A2 | |
| SCHEMBL13126455 | 0.81 | MAPK1 (0.46) | LMNASMN1; SMN2ALDH1A1RAB9ACYP1A2 | |
| SCHEMBL1841049 | 0.81 | MAPK1 (0.50) | LMNASMN1; SMN2ALDH1A1RAB9ACYP1A2 | |
| SCHEMBL6153935 | 0.80 | MAPK1 (0.45) | LMNASMN1; SMN2ALDH1A1RAB9ACYP1A2 | |
| SCHEMBL13462878 | 0.80 | SMN1; SMN2 (0.58) | LMNASMN1; SMN2ALDH1A1RAB9ACYP1A2 | |
| SCHEMBL841372 | 0.80 | LMNA (0.54) | LMNASMN1; SMN2ALDH1A1RAB9ACYP1A2 | |
| SCHEMBL7179952 | 0.80 | MAPK1 (0.45) | LMNASMN1; SMN2ALDH1A1RAB9ACYP1A2 | |
| SCHEMBL6155240 | 0.80 | MAPK1 (0.45) | LMNASMN1; SMN2ALDH1A1RAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | LMNA 1467/4885SMN1; SMN2 3120/4885ALDH1A1 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.